Navigation Links
Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid,Arthritis Compared to a Current Standard of Care

NUTLEY, N.J., June 15, 2007 /PRNewswire/ -- Results of the Option (TOcilizumab Pivotal Trial in Methotrexate Inadequate respONders) trial, the first multinational Phase III study outside of Japan, showed that patients treated with Actemra (either 4mg/kg or 8mg/kg) plus methotrexate achieved a significant and clinically important improvement in the signs and symptoms of moderate to severe rheumatoid arthritis (RA) compared to patients treated with placebo and methotrexate, a current standard of care. The data were presented today at the European Congress of Rheumatology (ECR) held by the European League Against Rheumatism (EULAR) in Barcelona, Spain.

In the 623-patient study, 58.5% of patients receiving the combination of ACTEMRA(TM) (8mg/kg) and methotrexate achieved at least a 20% improvement (ACR20) in RA symptoms compared with 26.5% of patients receiving placebo plus methotrexate after 24 weeks. The data also showed that 79.5% of patients in the ACTEMRA(TM) (8mg/kg) plus methotrexate group responded with moderate to good improvements in RA symptoms (EULAR response) compared to 34.8% for those treated with placebo and methotrexate at 24 weeks. ACTEMRA(TM) was generally well tolerated; the most common adverse events reported more frequently in the ACTEMRA(TM) arms of the OPTION trial were upper respiratory tract infection, nasopharyngitis and headache.

Other parameters measured in the study included C-reactive protein (CRP), a marker of inflammation, fatigue and hemoglobin. Patients in the ACTEMRA(TM) 8 mg/kg group showed a rapid lowering of CRP levels within two weeks, while fatigue scores showed that patients in the ACTEMRA(TM) group experienced a reduction in fatigue and a rapid improvement in hemoglobin levels. Low levels of hemoglobin are usually associated with anemia (reduction in red blood cells) that can result in tiredness and fatigue.

"There is a critical need for new therapies to treat moderate to severe RA patients, and these results suggest that IL-6 inhibition is an encouraging anti-inflammatory mechanism for reducing disease symptoms," said Mark C. Genovese, M.D., Associate Professor of Medicine at Stanford University School of Medicine.

ACTEMRA(TM) is the first humanized interleukin-6 (IL-6) receptor- inhibiting monoclonal antibody and represents a novel mechanism of action for the treatment for RA. Studies suggest that reducing the activity of IL-6, one of several key cytokines involved in the inflammatory process, may reduce inflammation of the joints, prevent long-term damage and relieve certain systemic effects of RA such as decreased hemoglobin, fatigue and osteoporosis.

"These study results underscore the potential for ACTEMRA(TM) to become a new treatment option for RA," said Lars Birgerson, M.D., Ph.D., Vice President, Global Head Medical Affairs, Roche. "We are hopeful that the ongoing Phase III trials will translate into improved clinical outcomes for patients."

About Rheumatoid Arthritis

Rheumatoid arthritis is a progressive, systemic autoimmune disease characterized by inflammation of the membrane lining in joints. This inflammation causes a loss of joint shape and function, resulting in pain, stiffness and swelling, ultimately leading to irreversible joint destruction and disability. RA affects more than 21 million people worldwide with approximately 2.5 million people affected in the United States. RA may also shorten life expectancy by affecting major organ systems and after 10 years, less than 50% of patients can continue to work or function normally on a day- to-day basis.

About the Study

The OPTION trial is a three-arm, randomized, double-blind, controlled Phase III study designed to evaluate the safety and efficacy of ACTEMRA(TM) plus methotrexate compared to placebo plus methotrexate in patients with moderate to severe RA who had an inadequate response to methotrexate alon e. Patients received ACTEMRA(TM) intravenously (either 4mg/kg or 8mg/kg) every 4 weeks plus methotrexate weekly, or placebo infusions plus methotrexate weekly, for 24 weeks. The study enrolled patients at 73 trial sites in 17 countries outside the United States, and is one of five Phase III trials designed to study ACTEMRA(TM) as a potential new treatment for RA.

Data from the study were analyzed to determine patients' response to treatment by using three standard assessments: ACR score(1), developed by the of Rheumatology (ACR), DAS28(2), a measurement of RA disease activity, and EULAR(3), a measurement of treatment response.

In the study, 43.9% of patients treated with ACTEMRA(TM) (8mg/kg) plus methotrexate achieved at least a 50% (ACR50) reduction in symptoms compared to 10.8% of patients receiving placebo and methotrexate; ACR70 was achieved in 22% of the treatment group versus 2% in the control group. At 24 weeks, disease remission, as measured by DAS28 (<2.6), was achieved by 28% of patients treated with ACTEMRA(TM) 8mg/kg plus methotrexate compared to 1% of those in the placebo and methotrexate group. At 24 weeks, the difference in the reduction of DAS28 from baseline was greater and statistically significant (p<0.0001) in patients treated with ACTEMRA(TM) 8mg/kg plus methotrexate (-3.43) compared to those in the placebo and methotrexate group (-1.55). According to the EULAR response, a good/moderate response was seen in 79.5% and 61.9% of patients receiving ACTEMRA(TM) plus methotrexate 8mg/kg and 4mg/kg, respectively, compared to 34.8% of patients receiving placebo plus methotrexate.

About ACTEMRA(TM) (tocilizumab)

ACTEMRA(TM) is the first humanized interleukin-6 (IL-6) receptor- inhibiting monoclonal antibody studied for the treatment of RA. Roche and Chugai have initiated a collaborative Phase III clinical development program in RA that is underway outside Japan with more than 4,000 patients have been recruited in 41 countries including several European countries and the USA. The compound is not currently approved in the United States.

The most common adverse events reported in ACTEMRA(TM) global clinical studies are upper respiratory tract infections, headache, nasopharyngitis and hypertension. As with other biological disease modifying anti-rheumatic drugs (DMARDs), serious infections have been reported in some patients treated with ACTEMRA(TM).

About Roche

Hoffmann-La Roche Inc. (Roche), based in Nutley, N.J., is the U.S. pharmaceuticals headquarters of the Roche Group, one of the world's leading research-oriented healthcare groups with core businesses in pharmaceuticals and diagnostics. For more than 100 years in the U.S., Roche has been committed to developing innovative products and services that address prevention, diagnosis and treatment of diseases, thus enhancing people's health and quality of life. An employer of choice, in 2006, Roche was named one of the Top 20 Employers (Science magazine), ranked the No. 1 Company to Sell For (Selling Power), and one of AARP's Top Companies for Older Workers, and in 2005, Roche was named one of Fortune magazine's Best Companies to Work For in America. For additional information about the U.S. pharmaceuticals business, visit our websites: http://www.rocheusa.com or www.roche.us.

    (1) ACR20, ACR50 and ACR70 represent the percentage of reduction (20%, 50%

        or 70%) in certain RA symptoms and measures the number of tender

        and swollen joints, pain, patient's and physician's global assessments

        and certain laboratory markers. An ACR70 response is considered

        exceptional and represents a significant improvement in a patient's

        condition.

    (2) The Disease Activity Score (DAS)28 is a combined index that measures

        disease activity in patients with RA. It combin
es information from 28

        tender and swollen joints (range 0-28), erythrocyte sedimentation

        rate, and a general health assessment on a visual analog scale. The

        level of disease activity is interpreted as low (DAS28 less than or

        equal to 3.2), moderate (3.2 < DAS28 less than or equal to 5.1) or

        high (DAS28 >5.1). DAS28 <2.6 corresponds to being in remission

        according to the criteria of the American Rheumatism Association (ARA).

    (3) The EULAR response criteria is based on the individual amount of

        change in DAS and the DAS value (low, moderate, high disease activity)

        reached to classify patients as good, moderate and non-responders.

CONTACT: Ginny Valenze of Roche, Office, +1-973-562-2783, Cell,+1-973-943-9219, ; or Becky Lauer of ManningSelvage & Lee, Office, +1-212-468-4125, Cell, +1-917-592-9260, virginia.valenze@roche.com becky.lauer@mslpr.com

Web site: http://www.rocheusa.com/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
2. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
3. Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
4. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
5. Next Safety, Inc.s Innovative Drug Delivery System Will Replace Cigarettes and Significantly Advance Pulmonary Medication Delivery
6. Ivivis PEMF Technology Significantly Improves Neuron Survival in Parkinsons Disease Model, Study Finds
7. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
8. The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
9. Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients
10. MabThera Significantly Extends Survival And Cures More Patients With Aggressive Lymphoma Than Chemotherapy Alone
11. Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... , February 8, 2016 ... new market research report "Ablation Technologies Market by Product ... Cancer, Pain Management, Cosmetic Surgery, Ophthalmology, Gynecology) - Global ... the global market over the forecast period of 2015 ... Billion by 2020, at CAGR of 10.5% from 2015 ...
(Date:2/8/2016)... Pa. , Feb. 8, 2016   ... November Research Group (NRG),s pharmacovigilance technology services ... system-related consulting services and an Oracle Argus Specialized ... services to Life Sciences companies. ... and expands HighPoint,s life sciences capabilities and provides ...
(Date:2/8/2016)...  As part of a major growth and expansion initiative, ... Lori Chmura as President of Dune Inc., its ... Chmura,s extensive experience in the medical device space will play ... --> --> In ... sales, marketing and operational functions in the U.S. She is ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... Remember the old saying “rub ... According to Perry A~, author of “Calcium Bentonite Clay” the health benefits of integrating ... balancing and detoxifying the body. , A former motivational speaker, Perry A~ has since ...
(Date:2/8/2016)... ... , ... FileHold's document management software has been implemented by ... environment for FileHold software that is pay per user subscription-based and also does ... FileHold web services API. DocuSyst also advises clients on fully functioning back up ...
(Date:2/8/2016)... ... February 08, 2016 , ... GrassrootsHealth published data from its ... 2 diabetes in the GrassrootsHealth cohort with substantially higher vitamin D levels than ... public health,” states Carole Baggerly, Director of GrassrootsHealth, “the safety and benefits ...
(Date:2/8/2016)... ... , ... TopConsumerReviews.com recently awarded their highest five-star rating to a product from ... a cluster of melanin when exposed to sunlight. Although most moles are benign and ... embarrassment. Historically, mole removal has involved a painful, often expensive visit to ...
(Date:2/8/2016)... NV (PRWEB) , ... February 08, 2016 , ... Guruji ... February 9th, 10th and 11th, 2016 in honor of his birthday on February 10th. ... true happiness. Mahendra Trivedi is known by over 250,000 people from over 40 ...
Breaking Medicine News(10 mins):